lebrikizumab
lebrikizumab is listed in the FDA National Drug Code directory with 2 NDC codes. Available dosage form: liquid.
Drug Details
- Generic Name
- lebrikizumab
- Brand Names
- N/A
- Application Number
- Sponsor
- SAMSUNG BIOLOGICS Co., Ltd.
- NDC Codes
- 2
- Dosage Forms
- LIQUID
- Routes
- N/A
- Active Ingredients
- LEBRIKIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. ( 1 )